Cypralis has entered into a collaboration with Janssen Pharmaceuticals Inc., facilitated by Johnson & Johnson Innovation, to develop new cyclophilin inhibitors for neurodegenerative diseases. The terms were not disclosed.   Cypralis focuses on the discovery of therapeutics for the modulation of peptidyl-prolyl isomerases (PPIases). Cyclophilin inhibitors on the market or in development are non-selective between the four commonly screened cyclophilin isoforms A, B, C and D. Cypralis and Jan...